Senzime expands US sales team and signs additional distribution agreements
“I am proud to say that our strategy is now materializing in the US. Bringing distributors Clinical Technology and Co-Medical on board together with a direct sales team gives us a strong and agile position to transform the US market and introduce the cutting-edge TetraGraph technology to physicians nationwide”, says Pia Renaudin, CEO Senzime.
Senzime Inc.’s President & General Manager Christopher Estes has together with Neal Smith, US VP Sales initiated the recruitment of a direct sales force that will be ready to meet accumulated demands as US hospitals now are restarting elective surgery procedures.
The US is the largest medical device market in the world representing 40 percent of global sales. By 2023, it is expected to grow to $208 billion. The country has more than 6,000 hospitals.
Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph is based on over 10 years of R&D and uses advanced algorithms and EMG-technology to stimulate, analyze and display the patient’s muscle function in real-time.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: email@example.com
TO THE EDITORS
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org is Certified Adviser for Senzime. www.senzime.com